Johannes Engelbrecht, MD

Vergelegen Medi-Clinic
Cape Town, Western Cape, South Africa

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• LB1529 - Randomized, Controlled Phase 3 Study of anti-C5a Vilobelimab’s Effect on Mortality in Critically Ill COVID-19 Patients: A Therapy for Viral Pneumonia

  Friday, October 21, 2022
  1:55 PM – 2:05 PM US ET